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A hallmark of all solid tumor malig-nancies is the ability to invade the
surrounding tissue and/or metastasize to
distant sites. Tumors cells have altered
signaling pathways which that to cytos-
keleton activation and migration. Myriad
studies have attempted to identify specific
adhesion molecule(s) expressed in solid
tumor cells that correlate with tumor cell
migrative and invasive behaviors. Among
such candidate molecules is hyaluronan
(HA), the major glycosaminoglycan com-
ponent of extracellular matrix (ECM).
HA serves not only as a primary con-
stituent of connective tissue extracellular
matrices but also functions as a bio-
regulatory molecule. Pertinently, HA is
enriched in many types of tumors. HA is
capable of binding to CD44 which is a
ubiquitous, abundant and functionally
important receptor expressed on the
surface of many normal cells and tumor
cells. Several lines of evidence indicate
that CD44 selects its unique downstream
effectors and coordinates downstream,
intracellular signaling pathways that
influence multiple cellular functions.
Certain microRNAs [(miRNAs), small
RNA molecules with ~20–25 nucleotides]
have been shown to play roles in regulat-
ing tumor cell migration, invasion, sur-
vival and chemotherapy resistance. In this
article, a special focus is placed on the
role of HA-mediated CD44 interaction
with unique signaling molecules in activ-
ating intracellular miRNA-signaling and
RhoGTPase functions leading to the
concomitant onset of tumor cell activities
(e.g., tumor cell migration, invasion,
survival and chemoresistance) and tumor
progression. This new knowledge could
serve as groundwork for the future
development of new drug targets to
inhibit HA/CD44-mediated oncogenic
signaling and cancer progression.
Tumor invasion and metastasis are the
primary causes of morbidity in cancer
patients. It is now certain that oncogenic
signaling and cytoskeleton function are
directly involved in breast tumor cell
growth, migration and invasion of sur-
rounding tissue and metastasis1. For
example, solid tumor cancers (e.g., breast
cancer or head and neck cancer) often
develop from epithelial tissues.1,2 The
resulting tumors (carcinomas) are very
heterogeneous—ranging from very slow
growing to highly-aggressive, metastatic
forms that are resistant to chemotherapy.2
Both breast carcinomas in situ (either
ductal or lobular in origin) and head and
neck squamous carcinoma cells (HNSCC)
can progress to infiltrating carcinomas
in the stroma, and finally metastasize to
distant tissues (most often bone, lung,
liver or brain) via the extensive lym-
phatic network.1,2 Diagnosis of whether
a lesion is benign or malignant is often
difficult since definitive cancer-specific
markers are lacking. Furthermore, the
basic cellular and molecular processes
underlying tumor cell migration, invasion
and metastasis are poorly understood.
It is quite clear, however, that cell
membrane-cytoskeleton interactions are
generally involved in tumor cell motility,
invasion of surrounding tissue and meta-
stasis.1,2 In particular, it is known that
both cytoskeletal proteins and actin-
cytoskeleton network are required for
tumor cell movement and infiltration
of surrounding tissue.1,2 The details of
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this process, however, remain to be
determined.
Hyaluronan (HA) and CD44
in Tumor Progression
A number of studies have been aimed at
identifying specific adhesion molecule(s)
expressed solid tumor cells that correlate
with tumor cell migrative and invasive
behaviors. Among such candidate mole-
cules is hyaluronan (HA) which is a non-
sulfated, unbranched glycosaminoglycan
consisting of repeating disaccharide units,
D-glucuronic acid and N-acetyl-D-gluco-
samine.3 HA, which is detected in the
extracellular matrix (ECM) of most mam-
malian tissues, is synthesized by specific
HA synthases3 and digested into various
smaller-sized molecules by hyaluroniases.4
Most importantly, HA has been found to
accumulate at tumor cell attachment sites
and appears to play an important role in
promoting tumor cell-specific behaviors.5
In cancer patients, HA concentrations are
usually higher in malignant tumors than in
corresponding benign or normal tissues,
and in some tumor types the level of HA is
predictive of malignancy.
CD44, a HA receptor denotes a family
of cell-surface glycoproteins which are
expressed in a variety of human solid
neoplasms, particularly those classified as
breast carcinomas and/or head neck
squamous cell carcinoma (HNSCC).6,7
Overexpression of CD44 has been shown
to be closely associated with breast tumor
and HNSCC growth, migration, invasion
and metastasis.6,7 Nucleotide sequence
analyses reveal that many CD44 isoforms
(derived from alternative splicing mechan-
isms) are variants of the standard form,
CD44s. The presence of high levels of
CD44 variant (CD44v) isoforms is emer-
ging as an important metastatic tumor
marker in a number of cancers including
human breast and head and neck can-
cers.6,7 Recent studies have shown that
CD44 is also expressed in tumor stem
cells which have the unique ability to
initiate tumor cell-specific properties. In
fact, CD44 is proposed to be one of the
important surface markers for cancer stem
cells. All CD44 isoforms contain a HA-
binding site in their extracellular domain
and thereby serve as a major cell surface
receptor for HA.6,7 Both CD44v isoforms
and HA are overexpressed at sites of tumor
attachment.6,7 It has been determined that
HA binding to CD44v isoforms affects
both cell adhesion to extracellular matrix
(ECM) components, and is involved in
the stimulation of a variety of tumor
cell-specific functions (e.g., cytoskeleton
activation, tumor cell migration/invasion,
tumor cell growth/survival and chemore-
sistance) leading to tumor progression.6,7
Lymphatic vessel endothelial hyaluro-
nan receptor-1 (LYVE-1) shares at least
43% of sequence homology with CD44.
The physiological functions of LYVE-1
include serving as a receptor for HA and
facilitating the transport and metabolism
of HA in the extracellular matrix. It has
also been shown that LYVE-1 is involved
in adherence of tumor cells8 and may
also promote tumor lymph node meta-
stasis and lymphatic invasion. Another
HA receptor, RHAMM (receptor for
hyaluronan-mediated motility), has been
shown to interact with CD44. Importantly,
the binding between RHAMM and CD44
activates ERK1/2 signaling and promotes
tumor cell motility.9 The fact that CD44,
LYVE1 and RHAMM display a numbers
of similarities (e.g., adhesion, motility and
signaling) suggests all three HA receptors
are involved in HA-associated tumor pro-
gression. However, in this short review, I
will only focus on HA-regulated CD44
signaling and function in regulating
oncogenesis and tumor progression.
Role of HA/CD44 in Activating
RhoA/RhoC Signaling and Rho-
Kinase (ROK) Function During
Tumor Cell Migration and Invasion
Members of the Rho subclass of the
Ras superfamily [small molecular weight
GTPases (e.g., RhoA, Rac1 and Cdc42)]
act as molecular switches that alternate
between GTP- and GDP-bound states.
The “activated” GTP-bound enzymes
preferentially interact with downstream
effector molecules that modulate effector
activities.10 Previous work has indicated
that HA promotes the interaction between
CD44 and several Rho-specific guanine
nucleotide exchange factors (e.g.,
p115RhoGEF and LARG),6 thereby upre-
gulating RhoA (a member of the Rho
subclass of the Ras superfamily), leading to
altered cytoskeleton-mediated cell func-
tions.6 For example, activation of RhoA
signaling has been shown to be involved in
cytoskeleton-associated functions.6
Activated RhoA has been shown to
induce membrane protrusion in epithelial
cells.6 RhoC, which shares at least 85%
sequence homology with RhoA, also parti-
cipates in remodeling of the cytoskele-
ton.11 Accumulating evidence suggests
that both RhoA and RhoC are critical for
breast tumor invasion and/or metastasis.11
In particular, a correlation between the
invasion activity of different tumor cells
and the requirement of RhoA/RhoC-
activated signaling has been suggested.
Several different enzymes have been iden-
tified as possible downstream targets for
RhoA/RhoC signaling. One such enzyme
is Rho-Kinase (ROK-also called Rho-
associated kinase) which is a serine-
threonine kinase known to interact with
Rho in a GTP-dependent manner.6,12 This
enzyme has been shown to regulate
cytoskeleton function by phosphorylating
several important cytoskeletal regulators
including the myosin-binding subunit
(MBS) of myosin phosphatase, calponin,
adducin and LIM kinase. HA-CD44
interaction promotes RhoA-activated
ROK phoshorylation of Ins(1,4,5)P3
receptors, Gab-1 and NHE1 leading to
cytoskeleton activation, cell proliferation
and migration.6
ROK is also involved in the “cross-talk”
between Ras and Rho signaling leading
to cellular transformation.6 A previous
study determined that ROK also is res-
ponsible for the phosphorylation of CD44-
associated cytoskeletal proteins during
actin filament and plasma membrane
interaction. When ROK is overexpressed
or constitutively activated, changes in
actin cytoskeleton organization occur that
are similar to those observed during
normal Rho-activated conditions.13 ROK
is overexpressed in breast tumor cells and
is capable of phosphorylating the cyto-
plasmic domain of CD44.13 Moreover,
phosphorylation of the cytoplasmic
domain of CD44 by ROK enhances its
binding interaction with the cytoskeletal
protein, ankyrin.13 Overexpression of the
Rho-binding domain (a dominant-negative
form) of ROK by transfecting breast
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tumor cells with RB cDNA induces
reversal of tumor cell-specific pheno-
types.13 These findings support the
notion that ROK plays a pivotal role in
CD44-cytoskeleton interaction and the
Rho-mediated oncogenic signaling that is
required for membrane-cytoskeleton func-
tion and metastatic tumor cell migration.
However, the cellular and molecular
mechanisms involved in the regulation
of RhoGTPase and ROK expression





MicroRNAs (miRNAs) are evolutionarily
conserved and function as negative regu-
lators of gene expression by inhibiting the
translation of mRNAs that contain com-
plementary target sites, referred to as the
“seed regions.”14 Previous data have
revealed that human miRNAs are pro-
cessed from capped and polyadenylated
transcripts, that are precursors to mature
miRNAs.15 In mammalian miRNA bio-
genesis, primary transcripts of miRNA
genes (pri-mRNAs) are subsequently
cleaved to produce an intermediate mole-
cule containing a stem loop of ~70
nucleotides (pre-mRNAs) by the nuclear
RNase III enzyme DROSHA, and
exported from the nucleus by Exportin
5.14 A second RNase III enzyme Dicer
then generates mature miRNA which is
loaded into the RNA-induced silencing
complex (RISC) in association with the
argonaute protein (Ago) that induces
silencing via the RNA interference path-
way. Although Dicer has an important
role in the silencing action of miRNAs,
recent studies have shown that silencing
can still occur in cells that lack Dicer. In
addition, the nuclear p68-RNA helicase
appears to be required in the uptake of
certain miRNAs into the silencing com-
plex.16 p68 belongs to a family of proteins
that are involved in RNA metabolism
processes such as translation and RNA
degradation. Computational predictions
of miRNA targets suggest that up to
30% of human protein-coding genes may
be regulated by miRNAs.17 This makes
miRNAs one of the most abundant classes
of post-transcriptional regulators of gene
expression.
A number of studies indicate that more
than 50% of microRNAs (miRNAs) are
located in cancer-associated genomic
regions or fragile sites, suggesting that
miRNA may be closely associated with
the pathogenesis of a variety of cancers.14
In particular, miRNA-10b was found to
be overexpressed in malignant glioma in
addition to the overexpression of RhoC
and uPAR which are contributors to
glioma invasion and migration.18 Further-
more, in human esophageal cancer cell
lines, Kruppel-like factor 4 (KLF4), a zinc
finger protein that has been identified
in several human tumors, is also a direct
target of miR-10b.19 Moreover, cell inva-
sion and metastasis were both shown to
be initiated by miRNA-10b in breast
cancer.20,21 Silencing of miR-10b with
antagomirs (an anti-miR-10 inhibitor)
both in vitro and in vivo significantly
decreases the amount of miR-10b and the
level of a functionally important miR-10b
target, HOXD10 resulting in decreased
metastasis.21,22 Thus, the miR-10b inhibi-
tor appears to be a promising candidate
for the development of new anti-metastasis
agents.
Recently, we discovered a new HA/
CD44-mediated signaling mechanism that
regulates Twist-associated miR-10b pro-
duction.21 Specifically, we found that HA
binding to CD44 promotes the nuclear
translocation of Twist (a stem cell-related
transcription factor) and transcriptional
activation. Further analyses reveal that
miR-10b is controlled by an upstream
promoter containing Twist binding site(s),
while chromatin immunoprecipitation
(ChIP) assays demonstrate that stimu-
lation of miR-10b expression by HA/
CD44-specific and Twist-dependent in
breast tumor cells. This process results in
the reduction of a tumor suppressor
protein (HOXD10), RhoA/RhoC upregu-
lation, Rho-Kinase (ROK) activation and
breast tumor cell invasion. Treatment of
breast tumor cells with Twist-specific
small interfering RNAs (siRNAs) effec-
tively blocks HA-mediated Twist signal-
ing events, abrogates miR-10b production
and increases HOXD10 expression. Sub-
sequently, this Twist signaling inhibition
causes downregulation of RhoA/RhoC
expression and impairment of ROK-regu-
lated cytoskeleton function (e.g., tumor
cell invasion). To further evaluate the role
of miR-10b in RhoGTPase signaling,
breast tumor cells were also transfected
with a specific anti-miR10b inhibitor in
order to silence miR-10b expression and
block its target functions. These recent
results demonstrate that anti-miR-10b
inhibitor not only enhances HOXD10
expression, but also abrogates HA/CD44-
mediated tumor cell behaviors in breast
tumor cells21. Taken together, these find-
ings indicate that the HA-induced CD44
interaction with Twist plays a pivotal
role in miR-10b production leading to
the downregulation of tumor suppressor
protein (HOXD10), RhoGTPase-ROK
activation and tumor cell invasion. All of
these events are critical pre-requisite steps
for the acquisition of metastatic properties




A previous study using breast tumor cells
found that MDR1 expression and multi-
drug resistance is linked to a positive
feedback circuit involving HA, phosphoi-
nositide 3-kinase (PI3K) and ErbB2.23 In
addition, HA-CD44-induced Ca2+ mobili-
zation, Nanog/Stat-3 signaling, EGFR
activation and cytoskeletal protein
(ankyrin) have been shown to play an
important role in regulating drug resist-
ance.7,24 HA-CD44 interaction also influ-
ences topoisomerase II activity and
Etoposide cytotoxicity in head and neck
cancers.7 These findings suggest that
the HA-CD44 interaction is definitely
involved in multidrug resistance.
The gene networks orchestrated by
many oncogenic miRNAs are still largely
unknown, although some key targets have
been identified as being involved in solid
tumor progression.25,26 In particular, miR-
21 appears to play a critical role in tumor
cell survival, chemoresistance and tumor
progression.24,27-29 However, very little is
known concerning the regulation of miR-
21 and its function in solid tumor cancer.
Recently, we found that miR-21 can be
activated by HA/CD44-activated stem cell
marker (Nanog) signaling in both breast
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and head and neck cancer cell lines.24,29
For example, our previous work showed
that HA-CD44 interaction promotes
Nanog interaction with p68 and
DROSHA leading to biosynthetic proces-
sing and production of miR-21 in breast
tumor cells.30 These findings suggest that
HA/CD44-mediated Nanog signaling is
closely linked to miR-21 production and
function during oncogenesis.
Abnormal Stat-3 signaling also appears
to play a critical role in oncogenesis.
Previous studies showed that the func-
tional link between Nanog and Stat-3
exists in several different tumor cells.24,29,30
In our recent study we observed that HA-
CD44 binding activates nuclear localiz-
ation of Nanog which then forms a
complex with Stat-3 in head and neck
cancer cells.24 In particular, miR-21 is
controlled by an upstream promoter/
enhancer containing Stat-3 binding sites
in head and neck cancer cells, while
chromatin immunoprecipitation (ChIP)
assays demonstrate that stimulation of
miR-21 production by HA is Nanog/
Stat-3 complex-dependent in head and
neck cancer cells.24 Most importantly, an
anti-miR-21 inhibitor can enhance PDCD4
expression, and block HA/CD44-mediated
tumor functions (e.g., survival protein
expression, tumor cell growth and survival/
chemotherapy resistance) in HNSCC cells.
Thus, this newly-discovered HA/CD44-
Nanog/Stat-3 signaling pathway and
miR-21 production/function are highly
Figure 1. HA/CD44-mediated Twist signaling and miR-10b production leading to RhoGTPase upregulation and ROK activation leading to tumor cell
migration and invasion as well as tumor cell survival and growth. The proposed signaling events are described as follows: Step 1: HA binds to tumor cell
surface receptor, CD44. Step 2: HA induces CD44-Twist complex formation. Step 3: Twist translocates from the cytosol to the nucleus. Step 4: Twist then
interacts with the E-box region of miR-10b promoter. Steps 5 and 6: Twist binds to the E-box and induces miR-10b gene expression and miR-10
production. Steps 7 and 8: miR-10b then downregulates the tumor suppressor protein (HOXD10) and promotes tumor cell activation (e.g., RhoA/RhoC
upregulation, ROK activation and cytoskeleton reorganization). Step 8a: HA/CD44/miR-10b-activated RhoA-ROK enhances myosin phosphatase activity,
thereby generating actomyosin-mediated tumor cell migration and invasion. Step 8b: HA/CD44/miR-10b-activated RhoA-ROK stimulates IP3 receptor
phosphorylation, IP3 production and intracellular Ca2+ mobilization resulting in CaMKII activation. CaMKII then phosphorylates the cytoskeletal protein,
filamin, leading to cytoskeleton reorganization and tumor cell migration/invasion. Step 8c: HA/CD44/miR-10b-activated RhoA-ROK induces NHE1-
mediated extracellular acidification leading to an activation of low pH-dependent extracellular matrix (ECM) degradation enzymes required for ECM
modification and tumor cell migration and invasion. Step 8d: HA/CD44/miR-10 activated RhoA-ROK promotes certain cellular proteins including the linker
molecule, Gab-1 which then interacts with PI3 kinase leading to AKT activation and tumor cell survival and growth.
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innovative and should provide important
new drug targets to cause tumor cell
apoptosis and overcome chemotherapy
resistance in head and neck cancer cells.
Summary
HA/CD44-mediated tumor cell-specific
phenotypes are closely linked to the small
GTP-binding proteins such as RhoA
and RhoC. Activation of RhoGTPases
(e.g., RhoA and RhoC) and Rho-kinase
(ROK) has been shown to produce
specific structural changes in actin assem-
bly, cytoskeleton reorganization, trans-
criptional activation, tumor cell growth,
survival, migration and invasion. Our
current models for illustrating HA-
dependent and CD44-specific microRNA
(e.g., miR-10b and miR-21) signaling
pathways are described as follows:
(1) HA-CD44-regulated miR-10b sig-
naling and RhoGTPase/ROK activation
pathways. Specifically, HA binding to
tumor cell surface(s) (Fig. 1, Step 1)
promotes CD44 association with a tran-
scription factor, Twist (Fig. 1, Step 2).
Twist then translocates from the cytosol to
the nucleus (Fig. 1, Step 3) and interacts
with the E-box region of miR-10b pro-
moter (Fig. 1, Step 4), resulting in miR-
10b gene expression (Fig. 1, Step 5) and
mature miR-10b production (Fig. 1, Step
6). The resultant miR-10b then functions
to downregulate the tumor suppressor
protein (HOXD10) (Fig. 1, Step 7) and
promotes tumor cell activation (e.g.,
RhoA/RhoC upregulation, ROK activa-
tion and cytoskeleton reorganization)
(Fig. 1, Step 8). Subsequently, HA/
CD44-activated RhoA-ROK stimulates
myosin phosphatase activity, thereby activ-
ating myosin adenosine triphosphatase
(ATPase) and generating actomyosin-
mediated tumor cell migration and inva-
sion (Fig. 1, Step 8a). HA/CD44-activated
RhoA-ROK also induces Ins(1,4,5)P3
receptor phosphorylation, Ins(1,4,5)P3
Figure 2. HA/CD44-mediated Nanog signaling and miR-21 production leading to oncogenesis and chemoresistance in tumor cells. The proposed
signaling events are described as follows: Step 1: HA binds to tumor cell surface receptor, CD44. Step 2: HA promotes CD44 association with Nanog. Step
3: Nanog translocates from the cytosol to the nucleus. Step 4: Nanog interacts with the microprocessor complex containing the RNAase III (DROSHA) and
the RNA helicase (p68). Steps 4a and 5: Nanog also binds to Stat-3 and becomes associated with an upstream/enhancer region (containing Stat-3 binding
sites) of the miR-21 promoter, resulting in miR-21 gene expression and mature miR-21 production. Step 6: HA/CD44/activated miR-21 downregulates the
tumor suppressor protein (PDCD4). Step 7: HA/CD44/activated miR-21 promotes the expression of inhibition of survival proteins (survivin, c-IAP1/2 and
XIAP). Step 8: HA/CD44/activated miR-21 causes anti-apoptosis, survival and chemotherapy resistance in tumor cells.
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production and intracellular Ca2+ mobili-
zation resulting in CaMKII activation.
CaMKII then phosphorylates the cyto-
skeletal protein, filamin, leading to cyto-
skeleton reorganization and tumor cell
migration/invasion (Fig. 1, Step 8b).
In addition, HA/CD44-activated RhoA-
ROK promotes NHE1 phosphorylation.
Most importantly, the phosphorylation
of NHE1 by RhoA-ROK promotes
Na+-H+ exchange activity and extra-
cellular acidification leading to an activa-
tion of low pH-dependent extracellular
matrix (ECM) degradation enzymes
required for ECM modification and
tumor cell migration and invasion
(Fig. 1, Step 8c). Finally, HA-CD44
activation of RhoA-ROK appears to
phosphorylate certain cellular proteins
including the linker molecule, Gab-1.
Most importantly, phosphorylation of
Gab-1 by RhoA-ROK promotes Gab-1
interaction with Ins(1,4,5)P3 kinase
leading to AKT activation and tumor
cell survival and growth (Fig. 1, Step
8d). Thus, the results of these studies
elucidating the HA/CD44 signaling
pathway-specific mechanisms involved in
microRNA production and RhoGTPase
signaling are significant for the formula-
tion of future intervention strategies in
the treatment of solid tumor invasion and/
or metastasis.
(2) HA-CD44-regulated miR-21 sig-
naling and chemotherapy resistance path-
ways. HA binding to tumor cell surface(s)
(Fig. 2, Step 1) also promotes CD44 asso-
ciation with the stem cell marker, Nanog
(Fig. 2, Step 2) which then becomes trans-
located from the cytosol to the nucleus
(Fig. 2, Step 3) and interacts with (a) the
microprocessor complex containing the
RNAase III (DROSHA) and the RNA
helicase (p68) (Fig. 2, Step 4) and/or (b)
an upstream/enhancer region (containing
Stat-3 binding sites) of the miR-21 pro-
moter (Fig. 2, Step 4a), resulting in miR-
21 gene expression and mature miR-21
production (Fig. 2, Step 5). The resultant
miR-21 then functions to downregulate
the tumor suppressor protein (PDCD4)
(Fig. 2, Step 6). Subsequently, these
changes result in the expression of survi-
val proteins (e.g., survivin, c-IAP1/2 and
XIAP) (Fig. 2, Step 7) and stimulation of
anti-apoptosis, survival and chemoresis-
tance (Fig. 2, Step 8) in tumor cells.
Taken together, these findings suggest
that targeting HA/CD44-mediated Nanog
signaling pathways and miR-21 function
may provide a new drug target to
sensitize tumor cell apoptosis/death and
overcome chemotherapy resistance in
tumor cells.
Our current model suggests that the
close interactions between CD44 and its
selected binding partners play a pivotal
roles in promoting “cross-talk” among
various intracellular signaling pathways
(e.g., miRNAs and RhoGTPases) leading
to the concomitant onset of multiple
functions. The coordinated HA/CD44
activation of miRNAs (e.g., miR-10b and
miR-21) and RhoGTPase signaling as
well as the cytoskeleton as described in
both models (Figs. 1 and 2) may be a
possible mechanism underlying various
tumor cell-specific behaviors, transcrip-
tional activation, tumor cell growth,
survival, migration and invasion-all obvi-
ous prerequisites for tumor metastasis
and progression.
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